Abbott Laboratories (NYSE:ABT) Stock Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

Abbott Laboratories Stock Performance

Abbott Laboratories stock traded down $1.71 during mid-day trading on Friday, reaching $121.82. The company had a trading volume of 10,338,220 shares, compared to its average volume of 5,209,277. The company has a 50 day moving average of $126.01 and a 200-day moving average of $128.95. Abbott Laboratories has a 52 week low of $113.39 and a 52 week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The firm has a market cap of $211.83 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 2.02 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, meeting analysts’ consensus estimates of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. During the same quarter in the prior year, the business earned $1.21 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.1%. The ex-dividend date is Thursday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is currently 31.58%.

Wall Street Analyst Weigh In

A number of brokerages have commented on ABT. Wells Fargo & Company raised their price objective on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Sanford C. Bernstein raised their price objective on shares of Abbott Laboratories from $150.00 to $154.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Barclays raised their price target on shares of Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Weiss Ratings reissued a “buy (b-)” rating on shares of Abbott Laboratories in a report on Monday, December 29th. Finally, Daiwa Capital Markets boosted their price target on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $147.42.

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sharp Wealth Advisory LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $227,000. Hopwood Financial Services Inc. increased its position in shares of Abbott Laboratories by 6.9% during the 4th quarter. Hopwood Financial Services Inc. now owns 3,170 shares of the healthcare product maker’s stock valued at $397,000 after purchasing an additional 204 shares during the last quarter. Genesee Capital Advisors LLC grew its stake in shares of Abbott Laboratories by 7.8% during the 4th quarter. Genesee Capital Advisors LLC now owns 9,273 shares of the healthcare product maker’s stock worth $1,162,000 after acquiring an additional 669 shares during the period. BridgePort Financial Solutions LLC grew its stake in Abbott Laboratories by 3.7% in the 4th quarter. BridgePort Financial Solutions LLC now owns 2,591 shares of the healthcare product maker’s stock valued at $325,000 after buying an additional 92 shares in the last quarter. Finally, Aberdeen Group plc increased its holdings in shares of Abbott Laboratories by 1.2% in the fourth quarter. Aberdeen Group plc now owns 1,993,536 shares of the healthcare product maker’s stock worth $249,770,000 after purchasing an additional 23,817 shares during the period. Institutional investors own 75.18% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.